Research programme: gynaecological disorders therapeutics - Meditrina

Drug Profile

Research programme: gynaecological disorders therapeutics - Meditrina

Alternative Names: MPI 675

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Meditrina Pharmaceuticals
  • Class
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Female genital diseases

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gynaecological-disorders in USA (PO)
  • 06 Feb 2008 Meditrina Pharmaceuticals has completed a global licensing agreement with AstraZeneca for use of aromatase inhibitors
  • 27 Sep 2007 Preclinical trials in Gynaecological disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top